MARKET

DMAC

DMAC

Diamedica Therapeutics Inc
NASDAQ
4.060
+0.010
+0.25%
After Hours: 4.060 0 0.00% 16:04 05/23 EDT
OPEN
4.000
PREV CLOSE
4.050
HIGH
4.226
LOW
4.000
VOLUME
80.80K
TURNOVER
--
52 WEEK HIGH
6.82
52 WEEK LOW
2.140
MARKET CAP
174.11M
P/E (TTM)
-6.2868
1D
5D
1M
3M
1Y
5Y
1D
DiaMedica Therapeutics Announces Key Opinion Leader Webinar On DM199 For The Treatment Of Preeclampsia On Wednesday, May 28, 2025, At 8:00 AM ET
Benzinga · 5d ago
Weekly Report: what happened at DMAC last week (0512-0516)?
Weekly Report · 5d ago
DiaMedica Therapeutics’ Earnings Call Highlights Progress and Stability
TipRanks · 05/16 01:50
DiaMedica Elects Directors at Annual Meeting
TipRanks · 05/15 21:29
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
TipRanks · 05/15 13:03
Diamedica Therapeutics (DMAC) Gets a Buy from Lake Street
TipRanks · 05/15 12:59
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX)
TipRanks · 05/15 10:40
DIAMEDICA THERAPEUTICS ANNOUNCES POSTER PRESENTATION AT EUROPEAN STROKE ORGANISATION CONFERENCE – ESOC 2025
Reuters · 05/14 20:30
More
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

Webull offers DiaMedica Therapeutics Inc stock information, including NASDAQ: DMAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DMAC stock methods without spending real money on the virtual paper trading platform.